Latest and Greatest in Practical Application of CV Outcomes for T2D Drugs
Diabetes is among the major risk factors for cardiovascular disease (CVD), which takes the lives of approximately 2100 people each day in the United States.[Mozaffarian 2015] CVD is the major cause of morbidity and mortality for patients with diabetes, as common coexisting conditions such as hypertension, obesity, and dyslipidemia increase cardiovascular (CV) risk.[ADA 2015; Go 2013; Halter 2014] Compared with nondiabetic individuals, the incidences of myocardial infarction (MI) and stroke are increased 2- to 3-fold in patients with type 2 diabetes (T2D).[Ferrannini 2015]
The goal of this activity is to provide participants with an increased awareness of new data related to the effect of glucose-lowering drugs on cardiovascular disease, specifically, hospitalizations for heart failure, in patients with T2D.
Please Note: this course is housed on Medscape. Upon selecting 'Take Course,' you will be redirected to Medscape to compete the activity.
This activity is intended for diabetologists and endocrinologists, primary care physicians, and cardiologists who treat patients with type 2 diabetes (T2D).
Upon completion of this activity, participants will be able to:
- Have increased knowledge regarding the
- Emerging cardiovascular-related data for modern T2D agents
- New data related to risk for major adverse cardiac events for antihyperglycemic agents
- Have greater competence related to
- Strategies for adjusting T2D therapy based on recent cardiovascular outcomes trials data
- Individualized treatment of T2D in patients who also have cardiovascular disease and elevated cardiovascular risk
The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Association of Clinical Endocrinologists (AACE) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 AMA
- 1.25 Attendance